Last reviewed · How we verify

mTOR inhibitor (everolimus)

Hannover Medical School · FDA-approved active Small molecule

mTOR inhibitor (everolimus) is a mTOR inhibitor Small molecule drug developed by Hannover Medical School. It is currently FDA-approved for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Neuroendocrine tumors of pancreatic origin. Also known as: switch immunosuppression to everolimus.

Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.

Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation. Used for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Neuroendocrine tumors of pancreatic origin.

At a glance

Generic namemTOR inhibitor (everolimus)
Also known asswitch immunosuppression to everolimus
SponsorHannover Medical School
Drug classmTOR inhibitor
TargetmTOR (mammalian target of rapamycin)
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

mTOR is a central regulator of cell metabolism, growth, and survival. By blocking mTOR signaling, everolimus suppresses cell proliferation and angiogenesis, making it effective in cancers and certain proliferative diseases. It also has immunomodulatory effects that enhance T-cell activation in some contexts.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about mTOR inhibitor (everolimus)

What is mTOR inhibitor (everolimus)?

mTOR inhibitor (everolimus) is a mTOR inhibitor drug developed by Hannover Medical School, indicated for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Neuroendocrine tumors of pancreatic origin.

How does mTOR inhibitor (everolimus) work?

Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.

What is mTOR inhibitor (everolimus) used for?

mTOR inhibitor (everolimus) is indicated for Advanced renal cell carcinoma, Breast cancer (hormone receptor-positive, HER2-negative), Neuroendocrine tumors of pancreatic origin, Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex, Renal angiomyolipoma associated with tuberous sclerosis complex.

Who makes mTOR inhibitor (everolimus)?

mTOR inhibitor (everolimus) is developed and marketed by Hannover Medical School (see full Hannover Medical School pipeline at /company/hannover-medical-school).

Is mTOR inhibitor (everolimus) also known as anything else?

mTOR inhibitor (everolimus) is also known as switch immunosuppression to everolimus.

What drug class is mTOR inhibitor (everolimus) in?

mTOR inhibitor (everolimus) belongs to the mTOR inhibitor class. See all mTOR inhibitor drugs at /class/mtor-inhibitor.

What development phase is mTOR inhibitor (everolimus) in?

mTOR inhibitor (everolimus) is FDA-approved (marketed).

What are the side effects of mTOR inhibitor (everolimus)?

Common side effects of mTOR inhibitor (everolimus) include Stomatitis/mouth ulcers, Rash, Diarrhea, Fatigue, Nausea, Anemia.

What does mTOR inhibitor (everolimus) target?

mTOR inhibitor (everolimus) targets mTOR (mammalian target of rapamycin) and is a mTOR inhibitor.

Related